Showing results (81-90 of 207) with videos related to

Sort By:
Pageof 21
Plos One|March 28, 2008
Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injuryMatthew Siegel, Pavel Strnad, R Edward Watts, et al.
Plos One|March 14, 2012
Non-coding keratin variants associate with liver fibrosis progression in patients with hemochromatosisPavel Strnad, Ozlem Kucukoglu, Mariia Lunova, et al.
Digestive Diseases and Sciences|June 8, 2012
Diagnosis of hereditary hemochromatosis in the era of genetic testingChristiane Trieß, Guido von Figura, Manfred Stuhrmann, et al.
World Journal of Gastrointestinal Oncology|December 2, 2021
Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancerKatharina Joechle, Jessica Guenzle, Claus Hellerbrand, et al.
Gastroenterology|April 6, 2007
Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargementPavel Strnad, Masaru Harada, Matthew Siegel, et al.
FEBS Letters|April 18, 2006
Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formationPavel Strnad, Matthew Siegel, Diana M Toivola, et al.
Zeitschrift Fur Gastroenterologie|October 20, 2021
Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidatesPhilipp A Reuken, Stefanie Albers, Falk Rauchfuss, et al.
Human Mutation|April 1, 2006
Denaturing temperature selection may underestimate keratin mutation detection by DHPLCPavel Strnad, Tim Christian Lienau, Guo-Zhong Tao, et al.
Gynecologic Oncology|October 16, 2012
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancerHelena Robova, Lukas Rob, Michael J Halaska, et al.
BMC Medicine|August 20, 2015
Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injuryValentyn Usachov, Thomas J Urban, Robert J Fontana, et al.
Pageof 21